Hypothesis

In aging duodenum, intestinal stem cell (ISC) hyperproliferation and oxidative stress shift the balance of Wnt/β‑catenin and Notch signaling toward a differentiation program that favors L‑cell formation but simultaneously epigenetically represses the Gcg locus, reducing GLP‑1 output per cell. This mechanism explains the discordance between preserved L‑cell numbers and diminished incretin response in older individuals.

Mechanistic rationale

• ISC signaling imbalance – Aged ISCs show elevated Ccnd1/Cdk6 and Nrf2 activity [1]. Persistent Nrf2 activation can antagonize Wnt/β‑catenin transcription, biasing downstream targets toward Notch‑driven secretory lineages while dampening Wnt‑dependent Gcg enhancer accessibility.
• Lineage bias – Notch activation promotes commitment to the enteroendocrine lineage, particularly L‑cells, which have a longer turnover than K‑cells [3]. However, Notch intracellular domain (NICD) recruits histone deacetylases to the Gcg promoter, a repression documented in cultured enteroendocrine models [4].
• Oxidative stress overlay – Elevated ROS in aged ISCs oxidizes cysteine residues on key transcription factors (e.g., FOXO1), further reducing their ability to cooperate with β‑catenin at the Gcg enhancer. This creates a permissive chromatin state for Gip but a restrictive one for Gcg.
• Nerve‑EEC feedback – VIPergic innervation, which sustains L‑cell survival and GLP‑1 release [3], declines with age. Reduced VIP signaling lowers cAMP‑PKA activity, diminishing CREB‑mediated Gcg transcription and compounding the epigenetic block.

Together, these changes predict that aged duodenum will contain a normal or increased number of L‑cells but each cell will secrete less GLP‑1 in response to nutrient stimuli.

Testable predictions

1. Per‑cell secretion assay – Isolate duodenal crypts from young (3‑month) and old (24‑month) mice, generate organoids, and use a microfluidic single‑cell secretion platform to quantify GLP‑1 released per L‑cell after glucose or fatty acid challenge. Expect a significant drop in per‑cell GLP‑1 in aged organoids despite comparable L‑cell counts (immunostaining for GLP‑1).
2. Pathway interrogation – Treat aged organoids with:
   • A Nrf2 inhibitor (ML385) to reduce oxidative stress.
   • A Wnt agonist (CHIR99021) to restore β‑catenin signaling.
   • A Notch inhibitor (DAPT) to assess lineage shift. Measure Gcg mRNA, chromatin accessibility (ATAC‑seq at the Gcg enhancer), and GLP‑1 secretion. Prediction: Nrf2 inhibition or Wnt activation will rescue per‑cell GLP‑1 secretion, whereas Notch inhibition will increase K‑cell bias without improving GLP‑1 output per L‑cell.
3. Human validation – Obtain duodenal biopsies from younger (<35 yr) and older (>65 yr) donors, perform single‑cell RNA‑seq coupled with intracellular cytokine staining for GLP‑1. Correlate GLP‑1 mRNA/protein levels with expression signatures of Nrf2 target genes, Wnt activity, and Notch activity. Expect an inverse correlation between Nrf2/Wnt dysregulation and GLP-1 output per L-cell in the older cohort.
4. Nerve‑EEC link – Quantify VIP‑positive fiber density in the same biopsies and assess cAMP levels in sorted L‑cells. Predict reduced VIP density and lower cAMP in aged samples, which will correlate with diminished GLP-1 secretion.

Falsifiability

If single‑cell assays reveal no difference in per‑cell GLP-1 secretion between young and old duodenum, or if manipulating Nrf2/Wnt/Notch fails to alter GLP-1 output per L-cell despite changes in lineage composition, the hypothesis would be refuted. Similarly, demonstrating that GLP-1 deficiency in aging is solely due to L-cell loss (with unchanged per‑cell secretion) would invalidate the proposed mechanism.

Broader impact

Confirming this model would shift therapeutic focus from merely incretin‑based drugs to targeting stem‑cell signaling pathways or redox balance to restore endogenous GLP-1 production in age‑related metabolic decline.

[1] https://pmc.ncbi.nlm.nih.gov/articles/PMC5611984/ [2] https://www.pnas.org/doi/10.1073/pnas.1905722116 [3] https://pubmed.ncbi.nlm.nih.gov/40342092/ [4] https://pmc.ncbi.nlm.nih.gov/articles/PMC7320824/ [5] https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.694284/full